SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC-Reference-Cited by-同舟云学术

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC

Published:2023-08-02 Issue: Volume: Page:
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

An Fengxiao¹,Zhang Wenjing²,Guo Yuxian²,Shi Fuyan²,Kong Yujia²,Tang Liguo³,Han Caijing⁴,Wang Qinghua²

Affiliation:

1. Department of Clinical Laboratory, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong, China

2. Department of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China

3. Department of Orthopedics, Sunshine Union Hospital, Weifang 261061, Shandong, China

4. School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Reference47 articles.

1. Immune checkpoint inhibitors in melanoma.;Long;Lancet,2021

2. Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.;Wang;Cancers (Basel),2022

4. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.;Qin;Cancer Control,2022

5. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.;Zhang;Clin Cancer Res,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities;Scientific Reports;2024-04-02